Telix Reports Second Quarter 2022 Financial Results
MELBOURNE, Australia, July 21, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended30 June 2022. All figures are in AUD$ unless otherwise stated. All fi...
ZIRCON Phase III Kidney Cancer Imaging Study Completes Enrolment
MELBOURNE, Australia, July 11, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has dosed the final patient and completed recruitment into the Phase III pivotal study ZIRCON (Zirconium in Renal Cancer Oncology, NCT03849118) of its investiga...
Kevin Richardson appointed as CEO, Telix Americas
MELBOURNE and INDIANAPOLIS, July 11, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce thatKevin Richardson, a senior global executive with a career focus on sales, marketing and business operations in the oncology and radiopharmaceutical mar...
Telix and Invicro Advance AI Partnership
MELBOURNE, Australia and BOSTON, June 14, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has advanced a partnership with Invicro LLC (Invicro), a global, industry-leading imaging CRO, and part of REALM IDx, Inc., to develop an artificial...
Telix and Invicro Advance AI Partnership
MELBOURNE, Australia and BOSTON, June 14, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has advanced a partnership with Invicro LLC (Invicro), a global, industry-leading imaging CRO, and part of REALM IDx, Inc., to develop an artificial...
Jubilant Radiopharma Joins Illuccix® Pharmacy Partner Network
MELBOURNE, Australia and INDIANAPOLIS, June 13, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce that its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium Ga 68 gozetotide), is now available at selected pharmacies in ...
Telix and RefleXion Expand Partnership for Prostate Cancer Treatment
MELBOURNE, Australia and INDIANAPOLIS, June 10, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RefleXion Medical, Inc. (Hayward, California, U.S.) (RefleXion) today announced the signing of a co-development and commercialisation agreement, to expand the use ...
Telix to Present at Jefferies Healthcare Conference
MELBOURNE, Australia and INDIANAPOLIS, June 7, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) advises t...
Telix Showcasing Innovation in Theranostics at SNMMI
MELBOURNE, Australia and INDIANAPOLIS, June 7, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its presence at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting to be held inVancouver from June 11-14. Gallium-based pr...
Illuccix® Granted Transitional Pass-Through Payment Status
INDIANAPOLIS, May 31, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announced that its prostate cancer imaging agent Illuccix® (kit for preparation of gallium Ga 68 gozetotide injection) has been granted Transitional Pass-Through Payment Status by the U.S...
Illuccix® Reimbursement Milestone and Launch Updates: Pass-Through Status Granted in the U.S.
MELBOURNE, Australia and INDIANAPOLIS, May 30, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on the U.S. and Australian launch and reimbursement status for its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium (68...
First Patient Dosed in Phase II Renal Cancer Theranostics Study
MELBOURNE, Australia and INDIANAPOLIS, May 5, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in the 'STARLITE 2' Phase II study of the Company's investigational renal cancer therapy, TLX250 (177 Lu-DOTA-girentu...
Telix Further Strengthens European Distribution Network for Illuccix
MELBOURNE, Australia and LIÈGE, Belgium, April 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces agreements with Sociedade Avanço, Unipessoal, LDA (Avanço) and THP Medical Products Vertriebs GmbH (THP) for the distribution of Telix's prostate ca...
First Patients Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent
Physicians in Indiana, New York City, and Washington are among the first to administer Illuccix® – demonstrating coast-to-coast availability of this new imaging agent Typically diagnosed in men over 50, prostate cancer is the second leading cause of cancer death in American men, after lung cance...
ProstACT Update: TARGET Study Ethics Approval
MELBOURNE, Australia, April 12, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its ProstACT TARGET Phase II clinical trial of the Company's prostate cancer antibody therapy candidate TLX591 (177Lu-DOTA-rosopatamab), in patients experiencing a fir...
Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab
MELBOURNE, Australia and INDIANAPOLIS, April 11, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, "Telix", the "Company") today announces that it has entered into a licence agreement with Eli Lilly and Company ("Lilly") under which Telix is granted exclusive worldwide rights to devel...
PSMA-PET Imaging to be Funded through Medicare in Australia from July 2022
MELBOURNE, Australia, April 6, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) welcomes the listing of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) (PSMA-PET) imaging for patients with prostate cancer on the Medicare Benefits Sche...
Telix, GMS and Monash Awarded $23M Federal Government Funding as part of $71M Australian Precision Medicine Enterprise (APME) Project
MELBOURNE, Australia, April 4, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it is part of a $71.2 million Australian Precision Medicine Enterprise (APME) Project, which has been awarded$23 million in Federal Government grant funding under t...
Commercial Launch: Illuccix® Now Available to Order in the United States
MELBOURNE, Australia and INDIANAPOLIS, April 4, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium Ga 68 gozetotide), also known as68Ga-PSMA-11 injection, is now commercially...
Change of Composition of the Telix Board of Directors
* Non-Executive Director Oliver Buck to retire at the Annual General Meeting * Tiffany Olson, experienced U.S.-based pharma executive appointed as independent Non-Executive Director MELBOURNE, Australia and INDIANAPOLIS, March 31, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, T...
